Against which human papillomavirus types shall we vaccinate and screen? the international perspective

By N. Muñoz, F. Bosch, X. Castellsagué, Mireia Díaz, S. de Sanjosé, D. Hammouda, K. Shah, C. Meijer. International Journal of Cancer, 2004

1,271 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document (2010, background): “These HPV types are causally linked with 70% of cervical cancers in Europe [28, 29].”
Worldwide burden of cervical cancer in 2008. (2011, background): “Additionally, there are two HPV vaccines available that can prevent human papillomavirus type 16 and human papillomavirus type 18 infections, which jointly cause 70%–75% of all cervical cancers and 40%–60% of its precursors [6, 7].”
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. (2006, background): “If it is not possible to nclude all six additional types in next-generation vaccines, hen there are some regional differences in the priorities for PV types [8,9,11].”
The global health burden of infection‐associated cancers in the year 2002 (2006, background): “As HPV 16 and 18 are the dominant types involved in cervical cancer aetiology in all parts of the world, a vaccine against these two types should, in theory, be able to prevent some 70% of cases of cancer.(148)”